<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010397728</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010397728</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Drug Interactions</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Influence of Different Proton Pump Inhibitors on Activity of Cytochrome P450 Assessed by [<sup>13</sup>C]-Aminopyrine Breath Test</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Kodaira</surname><given-names>Chise</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Uchida</surname><given-names>Shinya</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamade</surname><given-names>Mihoko</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Nishino</surname><given-names>Masafumi</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Ikuma</surname><given-names>Mutsuhiro</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Namiki</surname><given-names>Noriyuki</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Sugimoto</surname><given-names>Mitsushige</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Watanabe</surname><given-names>Hiroshi</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Hishida</surname><given-names>Akira</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Furuta</surname><given-names>Takahisa</given-names></name>
<degrees>MD, PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010397728">First Department of Medicine, Hamamatsu University School of Medicine (Dr Kodaira, Dr Yamade, Dr Nishino, Dr Ikuma, Dr Hishida)</aff>
<aff id="aff2-0091270010397728">Department of Pharmacy Practice and Science, School of Pharmaceutical Sciences, University of Shizuoka (Dr Uchida, Dr Namiki)</aff>
<aff id="aff3-0091270010397728">Center for Clinical Research, Hamamatsu University School of Medicine (Dr Sugimoto, Dr Furuta)</aff>
<aff id="aff4-0091270010397728">Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School of Medicine (Dr Watanabe)</aff>
<author-notes>
<corresp id="corresp1-0091270010397728">Takahisa Furuta, MD, PhD, Center for Clinical Research, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan; e-mail: <email>furuta@hama-med.ac.jp</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>3</issue>
<fpage>432</fpage>
<lpage>439</lpage>
<history>
<date date-type="received">
<day>11</day>
<month>8</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>Aminopyrine is metabolized by cytochrome P450 (CYP) in the liver. The investigators evaluated influences of different PPIs on CYP activity as assessed by the [<sup>13</sup>C]-aminopyrine breath test ([<sup>13</sup>C]-ABT). Subjects were 15 healthy volunteers with different CYP2C19 status (5 rapid metabolizers [RMs], 5 intermediate metabolizers [IMs], and 5 poor metabolizers [PMs]). Breath samples were collected before and every 15 to 30 minutes for 3 hours after oral ingestion of [<sup>13</sup>C]-aminopyrine 100 mg on day 8 of each of the following regimens: control; omeprazole 20 mg and 80 mg, lansoprazole 30 mg, and rabeprazole 20 mg. Changes in carbon isotope ratios in carbon dioxide (<sup>13</sup>CO<sub>2</sub>/<sup>12</sup>CO<sub>2</sub>) in breath samples were measured by infrared spectrometry and expressed as delta-over-baseline (DOB) ratios (‰). Mean areas under the curve of DOB from 0 to 3 h (AUC<sub>0-3h</sub> of DOB) were significantly decreased by omeprazole 20 mg and lansoprazole 30 mg but not by rabeprazole 20 mg. Conversely, higher PPI dose (ie, omeprazole 80 mg) seemed to further decrease AUC<sub>0-3h</sub> of DOB in RMs but increased it in PMs. Omeprazole and lansoprazole at the standard doses inhibit CYP activity but rabeprazole does not, whereas high-dose omeprazole seems to induce CYPs.</p>
</abstract>
<kwd-group>
<kwd>[<sup>13</sup>C]-aminopyrine breath test</kwd>
<kwd>cytochrome P450</kwd>
<kwd>proton pump inhibitor</kwd>
<kwd>CYP2C19</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, and rabeprazole, have been widely used as potent inhibitors of gastric acid secretion. PPIs strongly inhibit gastric acid secretion by irreversibly binding to the proton pump (H<sup>+</sup>, K<sup>+</sup>-ATPase) in gastric parietal cells.<sup><xref ref-type="bibr" rid="bibr1-0091270010397728">1</xref>,<xref ref-type="bibr" rid="bibr2-0091270010397728">2</xref></sup> The major indications for PPIs are acid-related diseases, such as peptic ulcer, gastroesophageal reflux disease, Zollinger-Ellison syndrome, and the eradication of <italic>Helicobacter pylori</italic> infection in combination with antimicrobial agents such as clarithromycin, metronidazole, and amoxicillin.<sup><xref ref-type="bibr" rid="bibr3-0091270010397728">3</xref>,<xref ref-type="bibr" rid="bibr4-0091270010397728">4</xref></sup> Recently, prescription of a PPI has been recommended by the American College of Cardiology Foundation, the American College of Gastroenterology, and the American Heart Association for patients with a risk of peptic ulcer and/or patients taking 2 or more antiplatelet agents.<sup><xref ref-type="bibr" rid="bibr5-0091270010397728">5</xref>-<xref ref-type="bibr" rid="bibr7-0091270010397728">7</xref></sup> Therefore, PPI is now used in patients who are taking a variety of therapeutic agents.</p>
<p>PPIs are mainly metabolized in the liver by cytochrome P450 (CYP) 2C19. Several reports have described drug–drug interactions with PPIs via hepatic CYPs.<sup><xref ref-type="bibr" rid="bibr8-0091270010397728">8</xref></sup> Because patients often take various drugs for concomitant illnesses, a risk of drug–drug interactions exists, and such interactions may increase the risk of adverse drug events or altered efficacy of therapeutic agents.<sup><xref ref-type="bibr" rid="bibr9-0091270010397728">9</xref></sup> However, the effect of PPIs on CYP activity has not been fully elucidated.</p>
<p>Aminopyrine is metabolized in the liver by CYPs, such as CYP2C19, 1A2, 3A4, and 2C9, after absorption through the intestine.<sup><xref ref-type="bibr" rid="bibr10-0091270010397728">10</xref>,<xref ref-type="bibr" rid="bibr11-0091270010397728">11</xref></sup> During the metabolism of aminopyrine by CYPs, CO<sub>2</sub> is generated. Therefore, when [<sup>13</sup>C]-labeled aminopyrine is metabolized by CYPs, <sup>13</sup>CO<sub>2</sub> is generated. Accordingly, <sup>13</sup>CO<sub>2</sub> after ingestion of [<sup>13</sup>C]-aminopyrine is considered as a good marker of CYP activity, which is the so-called [<sup>13</sup>C]-aminopyrine breath test ([<sup>13</sup>C]-ABT).<sup><xref ref-type="bibr" rid="bibr12-0091270010397728">12</xref>,<xref ref-type="bibr" rid="bibr13-0091270010397728">13</xref></sup> As noted before, PPIs will be used in many patients treated with a variety of medicines. Therefore, drug–drug interaction associated with PPIs via P450 will be of a great clinical problem. Thus, we evaluated the influences of different PPIs on CYP activity using the [<sup>13</sup>C]-ABT.</p>
<sec id="section1-0091270010397728" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010397728">
<title>Subjects</title>
<p>Blood samples were obtained from 50 <italic>H pylori</italic>– seronegative healthy Japanese volunteers after obtaining written informed consent from each of them. After genotyping of these samples, we enrolled randomly selected 5 rapid metabolizers (RMs), 5 intermediate metabolizers (IMs), and 5 poor metabolizers (PMs) in this study after obtaining written informed consent again. Demographic characteristics of 15 subjects are demonstrated in <xref ref-type="table" rid="table1-0091270010397728">Table I</xref>. They had no history of peptic ulcer, hepatic disorders, cardiovascular disorders, renal diseases, or other serious conditions. Subjects had consumed no alcohol or taken any drugs for 1 month prior to this study. Smoking was prohibited during the study period. No significant differences in age, male/female ratio, or body weight were seen among the 3 CYP2C19 genotype groups (<xref ref-type="table" rid="table1-0091270010397728">Table I</xref>). All subjects provided written informed consent prior to enrollment.</p>
<table-wrap id="table1-0091270010397728" position="float">
<label>Table I</label>
<caption>
<p>Demographic Characteristics of Study Subjects Among CYP2C19 Genotype Status</p>
</caption>
<graphic alternate-form-of="table1-0091270010397728" xlink:href="10.1177_0091270010397728-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">RM (n = 5)</th>
<th align="center">IM (n = 5)</th>
<th align="center">PM (n = 5)</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2C19 genotype</td>
<td>*1/*1</td>
<td>*1/*2: n = 3</td>
<td>*2/*2: n = 0</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td>*1/*3: n = 2</td>
<td>*2*/3: n = 5</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>*3/*3: n = 0</td>
<td/>
</tr>
<tr>
<td>Age, y</td>
<td>21.2 ± 1.3</td>
<td>21.8 ± 0.5</td>
<td>22.6 ± 1.1</td>
<td>.141</td>
</tr>
<tr>
<td>Sex, n M/F</td>
<td>3/2</td>
<td>4/1</td>
<td>4/1</td>
<td>.687</td>
</tr>
<tr>
<td>Height, cm</td>
<td>167.6 ± 5.5</td>
<td>172.4 ± 5.3</td>
<td>171.4 ± 5.6</td>
<td>.370</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>57.6 ± 5.9</td>
<td>58.0 ± 7.2</td>
<td>61.0 ± 6.8</td>
<td>.687</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010397728">
<p>BMI, body mass index; IM, intermediate metabolizer; PM, poor metabolizer; RM; rapid metabolizer.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section3-0091270010397728">
<title>[<sup>13</sup>C]-ABT and Study Protocol</title>
<p>[<sup>13</sup>C]-ABT was performed as followed. After collection of baseline breath samples after overnight fasting, 100 mg of oral [<sup>13</sup>C]-aminopyrine (N,N-dimethyl-[<sup>13</sup>C]-aminopyrine; 99%) dissolved in 100 mL of water was dosed to each of the subjects. Breath samples were collected before and 15, 30, 45, 60, 75, 90, 105, 120, 150, and 180 minutes after oral [<sup>13</sup>C]-aminopyrine administration. Changes in the carbon isotope ratio (<sup>13</sup>CO<sub>2</sub>/<sup>12</sup>CO<sub>2</sub>) in carbon dioxide from breath samples were measured with infrared spectrometry (PocOne; Otsuka Electronics, Hirakata, Japan) and were expressed as a delta-over-baseline (DOB) ratio (‰), representing the change in <sup>13</sup>CO<sub>2</sub>/<sup>12</sup>CO<sub>2</sub> ratio in breath samples collected before and after [<sup>13</sup>C]-aminopyrine ingestion.</p>
<p>[<sup>13</sup>C]-ABT was performed with different regimens: control and after dosing with omeprazole 20 mg and 80 mg (Omepral, AstraZeneca Pharmaceutical, Osaka, Japan), lansoprazole 30 mg (Takepron, Takeda Pharmaceutical, Osaka, Japan), and rabeprazole 20 mg (Pariet, Eisai, Tokyo, Japan) for 8 days. The washout interval between different regimens was greater than 2 weeks.</p>
<p>Plasma concentrations of [<sup>13</sup>C]-aminopyrine were measured at 0, 0.5, 1, 2, and 3 hours after oral ingestion of [<sup>13</sup>C]-aminopyrine at the baseline regimen and at 2 omeprazole regimens (20 mg and 80 mg). Plasma omeprazole level was measured at 3.5 hours after omeprazole dosing. We then evaluated how each PPI influenced the pharmacokinetics of aminopyrine. The study protocol was approved by the Ethics Committee of Hamamatsu University School of Medicine.</p>
</sec>
<sec id="section4-0091270010397728">
<title>Genotyping of CYP2C19</title>
<p>CYP2C19 genotyping was performed using a PCR-RFLP method using DNA extracted from whole blood.<sup><xref ref-type="bibr" rid="bibr14-0091270010397728">14</xref></sup> Subjects were classified into 3 genotype groups: RMs (*1/*1); IMs (*1/*2 or *1/*3); and PMs (*2/*2, *3/*3, or *2/*3).</p>
</sec>
<sec id="section5-0091270010397728">
<title>Measurements of Plasma Concentration of [<sup>13</sup>C]-Aminopyrine and Omeprazole</title>
<p>Plasma concentrations of [<sup>13</sup>C]-aminopyrine were determined by high-performance liquid chromatography (HPLC)/mass spectrometry (LC/MS). Briefly, plasma samples (0.1 mL) and 20 ng of antipyrine (1 mL in methanol) as an internal standard were mixed and centrifuged at 10 000<italic>g</italic> for 10 minutes. A 10-µL aliquot was injected into the HPLC apparatus and analyzed using an analytical column (Symmetry C18, 5 µm, 2.1 mm × 150 mm; Waters, Milford, Massachusetts) and a guard column (Symmetry C18, 3.5 µm, 2.1 mm × 10 mm; Waters) with the mobile phase (methanol/0.1% formic acid, 70:30, vol/vol) delivered at a flow rate of 0.2 mL/min at 40°C. The mass spectrometer was operated in positive ionization mode with selected ion recording acquisition at 189.1 m/z for antipyrine and 234 m/z for [<sup>13</sup>C]-aminopyrine. The limit of quantification was 0.1 µg/mL, and the intra-assay coefficient of variation was less than 13.5%. The run time of the assay was 4.5 minutes. The retention times of antipyrine and [<sup>13</sup>C]-aminopyrine were 2.19 and 1.96 minutes, respectively.</p>
<p>Plasma concentrations of omeprazole were determined by LC/MS as previously reported,<sup><xref ref-type="bibr" rid="bibr15-0091270010397728">15</xref></sup> with minor modification.</p>
</sec>
<sec id="section6-0091270010397728">
<title>Statistical Analysis</title>
<p>Numerical values are given as mean ± standard deviation (SD). Pharmacokinetic parameters for [<sup>13</sup>C]-aminopyrine and omeprazole were estimated by noncompartmental analysis. Maximum plasma concentration (C<sub>max</sub>) and time at maximum plasma concentration (T<sub>max</sub>) were estimated directly from observed plasma concentration–time data. The area under the curve (AUC) for plasma concentration or DOB versus time from 0 to 3 hours after administration of [<sup>13</sup>C]-aminopyrine was calculated by the linear trapezoidal rule for the observed values. Statistically significant differences in pharmacokinetic and pharmacodynamic parameters among the 3 different CYP2C19 genotype groups were assessed using 1-way analysis of variance followed by Scheffé multiple comparison test. Presence or absence of changes in pharmacological parameters was assessed by paired <italic>t</italic> test. All <italic>P</italic> values were 2-sided, and <italic>P</italic> &lt; .05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section7-0091270010397728" sec-type="results">
<title>Results</title>
<sec id="section8-0091270010397728">
<title>Characteristics of Subjects in Relation to CYP2C19 Genotype Status</title>
<p><xref ref-type="table" rid="table1-0091270010397728">Table I</xref> summarizes demographic characteristics of study subjects among CYP2C19 genotype status. There were no statistically significant differences in means of age, height, and body weight and in male/female ratio among 3 CYP2C19 genotype groups.</p>
</sec>
<sec id="section9-0091270010397728">
<title>[<sup>13</sup>C]-ABT and Pharmacokinetics of [<sup>13</sup>C]-Aminopyrine</title>
<p><xref ref-type="fig" rid="fig1-0091270010397728">Figure 1</xref> shows the association of [<sup>13</sup>C]-ABT results with metabolic parameters of [<sup>13</sup>C]-aminopyrine. AUC<sub>0-3h</sub> of [<sup>13</sup>C]-aminopyrine showed a significant inverse correlation with AUC<sub>0-3h</sub> of DOB (<italic>R</italic><sup>2</sup> = 0.116, <italic>P</italic> = .042; <xref ref-type="fig" rid="fig1-0091270010397728">Figure 1A</xref>). Similarly, clearance of plasma [<sup>13</sup>C]-aminopyrine showed a significant association with AUC<sub>0-3h</sub> of DOB (<italic>R</italic><sup>2</sup> = 0.297, <italic>P</italic> = .002; <xref ref-type="fig" rid="fig1-0091270010397728">Figure 1B</xref>). Together, [<sup>13</sup>C]-ABT reflects the metabolic disposition of [<sup>13</sup>C]-aminopyrine and could offer a marker of hepatic CYP activity.</p>
<fig id="fig1-0091270010397728" position="float">
<label>Figure 1.</label>
<caption>
<p>Association of [<sup>13</sup>C]-aminopyrine breath test ([<sup>13</sup>C]-ABT) with pharmacokinetic parameters of [<sup>13</sup>C]-aminopyrine. (A) Area under the curve from 0 to 3 hours (AUC<sub>0-3h</sub>) of [<sup>13</sup>C]-aminopyrine shows a significant inverse association with AUC<sub>0-3h</sub> of delta-over-baseline (DOB) of [<sup>13</sup>C]-ABT. (B) Oral clearance of [<sup>13</sup>C]-aminopyrine shows a significant association with AUC<sub>0-3h</sub> of DOB of [<sup>13</sup>C]-ABT.</p>
</caption>
<graphic xlink:href="10.1177_0091270010397728-fig1.tif"/>
</fig>
</sec>
<sec id="section10-0091270010397728">
<title>Influences of PPIs on Pharmacokinetics of [<sup>13</sup>C]-ABT</title>
<p><xref ref-type="table" rid="table2-0091270010397728">Table II</xref> summarizes the pharmacokinetic parameters of [<sup>13</sup>C]-aminopyrine with or without omeprazole. Half-life (T<sub>1/2</sub>) of [<sup>13</sup>C]-aminopyrine after omeprazole 20 mg treatment was significantly longer than the control (<italic>P</italic> = .002). Similarly, oral clearance of [<sup>13</sup>C]-aminopyrine after dosing of omeprazole 20 mg was significantly decreased in comparison with the control (<italic>P</italic> = .048; <xref ref-type="table" rid="table2-0091270010397728">Table II</xref>).</p>
<table-wrap id="table2-0091270010397728" position="float">
<label>Table II</label>
<caption>
<p>Plasma Kinetic Parameters of [<sup>13</sup>C]-Aminopyrine With or Without Omeprazole 20mg Treatment (Adjusted Weight-Dose)</p>
</caption>
<graphic alternate-form-of="table2-0091270010397728" xlink:href="10.1177_0091270010397728-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Baseline</th>
<th align="center">After OPZ</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>T<sub>1/2</sub>, h</td>
<td>0.035 ± 0.020</td>
<td>0.056 ± 0.033</td>
<td>.002</td>
</tr>
<tr>
<td>CL<sub>oral</sub>, L/h</td>
<td>0.405 ± 0.204</td>
<td>0.323 ± 0.176</td>
<td>.048</td>
</tr>
<tr>
<td>T<sub>max</sub>, h</td>
<td>0.018 ± 0.011</td>
<td>0.833 ± 0.408</td>
<td>.313</td>
</tr>
<tr>
<td>C<sub>max</sub>, µg/mL</td>
<td>0.026 ± 0.011</td>
<td>0.026 ± 0.011</td>
<td>.827</td>
</tr>
<tr>
<td>AUC<sub>0-3h</sub>, h·µg/mL</td>
<td>0.052 ± 0.023</td>
<td>0.053 ± 0.022</td>
<td>.807</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0091270010397728">
<p>AUC<sub>0-3h</sub>, area under the curve from 0 to 3 hours; CL<sub>oral</sub>, oral clearance; C<sub>max</sub>, maximum drug concentration, OPZ, omeprazole; T<sub>1/2</sub>, half life-period; T<sub>max</sub>, time at maximum drug concentration.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="fig" rid="fig2-0091270010397728">Figure 2</xref> shows time course changes in DOB of [<sup>13</sup>C]-ABT with or without different PPIs. DOB of [<sup>13</sup>C]-ABT was decreased when omeprazole 20 mg was dosed 30 minutes before [<sup>13</sup>C]-aminopyrine ingestion in comparison with control. Similarly, lansoprazole 30 mg decreased the DOB of [<sup>13</sup>C]-ABT. However, rabeprazole 20 mg did not affect the DOB of [<sup>13</sup>C]-ABT in comparison with control.</p>
<fig id="fig2-0091270010397728" position="float">
<label>Figure 2.</label>
<caption>
<p>Time course changes of delta-over-baseline (DOB) of [<sup>13</sup>C]-aminopyrine with and without different proton pump inhibitors (PPIs). The mean of DOB of [<sup>13</sup>C]-aminopyrine was most decreased by omeprazole (OPZ) 20 mg in comparison with the control. Similarly, it was decreased by lansoprazole (LPZ) 30 mg. However, it did not change by rabeprazole (RPZ) 20 mg in comparison with the control. Bars indicate standard deviation (SD).</p>
</caption>
<graphic xlink:href="10.1177_0091270010397728-fig2.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig3-0091270010397728">Figure 3</xref> shows the influences of different PPIs on AUC<sub>0-3h</sub> of DOB. Mean AUC<sub>0-3h</sub> of DOB at the control level was 21.9 ± 6.0%·h, compared with 19.2 ± 5.4 %·h after omeprazole 20 mg, 19.6 ± 5.6%·h after lansoprazole 30 mg, and 21.2 ± 5.7%·h after rabeprazole 20 mg. Administration of omeprazole 20 mg and lansoprazole 30 mg significantly decreased AUC<sub>0-3h</sub> of DOB in comparison with the control (<italic>P</italic> = .021 and <italic>P</italic> = .018), whereas rabeprazole 20 mg did not.</p>
<fig id="fig3-0091270010397728" position="float">
<label>Figure 3.</label>
<caption>
<p>Influence of different proton pump inhibitors (PPIs) on area under the curve from 0 to 3 hours (AUC<sub>0-3h</sub>) of delta-over-baseline (DOB). The mean of AUC<sub>0-3h</sub> of DOB was significantly decreased by omeprazole (OPZ) 20 mg and lansoprazole (LPZ) 30 mg in comparison with the control, but not by rabeprazole (RPZ) 20 mg. Bars indicate standard deviation (SD).</p>
</caption>
<graphic xlink:href="10.1177_0091270010397728-fig3.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig4-0091270010397728">Figure 4</xref> shows the effect of CYP2C19 genotypes on DOB of [<sup>13</sup>C]-ABT. DOB of PMs was lower than those of IMs and RMs. Mean DOB in PMs, RMs, and IMs were 18.0 ± 5.8%·h, 23.6 ± 3.1%·h, and 24.1 ± 7.4%·h, respectively.</p>
<fig id="fig4-0091270010397728" position="float">
<label>Figure 4.</label>
<caption>
<p>Effect of CYP2C19 genotypes on delta-over-baseline (DOB) of [<sup>13</sup>C]-aminopyrine breath test ([<sup>13</sup>C]-ABT). The mean DOB in poor metabolizers (PMs) was lowest of the 3 CYP2C19 genotype groups. Bars indicate standard deviation (SD).</p>
</caption>
<graphic xlink:href="10.1177_0091270010397728-fig4.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig5-0091270010397728">Figure 5</xref> shows the influences of different PPIs on AUC<sub>0-3h</sub> for DOB of [<sup>13</sup>C]-ABT as a function of CYP2C19 genotypes. Omeprazole 20 mg significantly decreased AUC<sub>0-3h</sub> for DOB of [<sup>13</sup>C]-ABT in IMs. In contrast, no significant differences were observed with lansoprazole 30 mg or rabeprazole 20 mg.</p>
<fig id="fig5-0091270010397728" position="float">
<label>Figure 5.</label>
<caption>
<p>Influence of different proton pump inhibitors (PPIs) on area under the curve from 0 to 3 hours (AUC<sub>0-3h</sub>) for delta-over-baseline (DOB) of [<sup>13</sup>C]-aminopyrine breath test ([<sup>13</sup>C]-ABT) as a function of CYP2C19 genotype status. Omeprazole (OPZ) significantly decreased DOB in IMs of CYP2C19. Bars indicate standard deviation (SD). Con, control; IM, intermediate metabolizer; RM, rapid metabolizer; PM, poor metabolizer.</p>
</caption>
<graphic xlink:href="10.1177_0091270010397728-fig5.tif"/>
</fig>
</sec>
<sec id="section11-0091270010397728">
<title>Influences of Omeprazole 80 mg on [<sup>13</sup>C]-ABT</title>
<p><xref ref-type="fig" rid="fig6-0091270010397728">Figure 6</xref> compares the influences of omeprazole 20 mg and 80 mg on DOB as a function of CYP2C19 genotype status. In RMs, DOB appeared further decreased from 23.6 ± 3.1% to 21.9 ± 3.8% and 20.5 ± 5.1% increasing the dose of omeprazole from 20 mg to 80 mg (<xref ref-type="fig" rid="fig6-0091270010397728">Figure 6A</xref> and <xref ref-type="fig" rid="fig6-0091270010397728">6B</xref>). In IMs, omeprazole 20 mg significantly decreased DOB from 24.1 ± 7.4% to 18.7 ± 5.6% (<italic>P</italic> = .048); however, this decrease in DOB was ameliorated with omeprazole 80 mg (23.0 ± 4.5%) (<xref ref-type="fig" rid="fig6-0091270010397728">Figure 6C</xref> and <xref ref-type="fig" rid="fig6-0091270010397728">6D</xref>). In PMs, omeprazole 20 mg appeared to decrease DOB from 18.0 ± 5.8% to 17.1 ± 6.3%, but omeprazole 80 mg increased DOB to 21.3 ± 6.7% (<italic>P</italic> = .042 for control and .029 for omeprazole 20 mg) (<xref ref-type="fig" rid="fig6-0091270010397728">Figure 6E</xref> and <xref ref-type="fig" rid="fig6-0091270010397728">6F</xref>).</p>
<fig id="fig6-0091270010397728" position="float">
<label>Figure 6.</label>
<caption>
<p>Influence of omeprazole (OPZ) 20 mg and 80 mg on delta-over-baseline (DOB) of [<sup>13</sup>C]-aminopyrine breath test ([<sup>13</sup>C]-ABT) as a function of CYP2C19 genotype status. (A) DOB of [<sup>13</sup>C]-ABT with or without OPZ 20 mg in rapid metabolizers (RMs) of CYP2C19. (B) DOB of [<sup>13</sup>C]-ABT with or without OPZ 80 mg in RMs of CYP2C19. (C) DOB of [<sup>13</sup>C]-ABT with or without OPZ 20 mg in intermediate metabolizers (IMs) of CYP2C19. (D) DOB of [<sup>13</sup>C]-ABT with or without OPZ 80 mg in IMs of CYP2C19. (E) DOB of [<sup>13</sup>C]-ABT with or without OPZ 20 mg in poor metabolizers (PMs) of CYP2C19. (F) DOB of [<sup>13</sup>C]-ABT with or without OPZ 80 mg in PMs of CYP2C19. (G) Influences of OPZ 20 mg or 80 mg on AUC<sub>0-3h</sub> of DOB (%·h) in RMs, IMs, and PMs of CYP2C19. DOB was most decreased by OPZ in a dose-dependent manner in RMs of CYP2C19 (compare A with B); however, this decrease was not statistically significant (G). That in IMs was decreased by OPZ 20 mg but not by OPZ 80 mg (C, D, and G). That in PMs seemed slightly decreased by OPZ 20 mg but significantly increased by OPZ 80 mg (E, F, and G). Bars indicate standard deviation (SD). o, without omeprazole; •, with omeprazole.</p>
</caption>
<graphic xlink:href="10.1177_0091270010397728-fig6.tif"/>
</fig>
<p>AUC<sub>0-3h</sub> of DOB appeared decreased with the dose of omeprazole in RMs (although statistically not significantly), that in IMs significantly decreased by omeprazole 20 mg but returned to the control level by omeprazole 80 mg, and that in PM did not decreased by omeprazole 20 mg but significantly increased by omeprazole 80 mg (<xref ref-type="fig" rid="fig6-0091270010397728">Figure 6G</xref>).</p>
<p>With omeprazole 20 mg, plasma concentration of omeprazole at 3.5 hours after administration was lowest in RMs and highest in PMs. Similarly, when omeprazole 80 mg was dosed, plasma concentration of omeprazole at 3.5 hours was the lowest in RMs and the highest in PMs. However, the PM/RM ratio of plasma omeprazole levels appeared to decrease after increasing the omeprazole dose from 20 mg to 80 mg. When plasma omeprazole dose was increased from 20 mg to 80 mg, omeprazole level increased approximately 3.4 times in RMs. However, in PMs, the increase in omeprazole level was smaller (1.8 times) than that in RMs (<xref ref-type="table" rid="table3-0091270010397728">Table III</xref>).</p>
<table-wrap id="table3-0091270010397728" position="float">
<label>Table III</label>
<caption>
<p>Plasma Concentration of Omeprazole 20 mg and 80 mg at 3.5 Hours After Administration Among Different CYP2C19 Genotype Status</p>
</caption>
<graphic alternate-form-of="table3-0091270010397728" xlink:href="10.1177_0091270010397728-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">RM (n = 5)</th>
<th align="center">IM (n = 5)</th>
<th align="center">PM (n = 5)</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn4-0091270010397728">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>OPZ 20 mg, ng/mL</td>
<td>164.8 ± 85.8</td>
<td>526.2 ± 377.4</td>
<td>650.3 ± 302.2<xref ref-type="table-fn" rid="table-fn5-0091270010397728">*</xref></td>
<td>.091</td>
</tr>
<tr>
<td>OPZ 80 mg, ng/mL</td>
<td>550.9 ± 304.5</td>
<td>1046.7 ± 402.9</td>
<td>1167.9 ± 496.7<xref ref-type="table-fn" rid="table-fn6-0091270010397728">**</xref></td>
<td>.084</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0091270010397728">
<p>IM, intermediate metabolizer; OPZ, omeprazole; PM, poor metabolizer; RM, rapid metabolizer.</p>
</fn>
<fn id="table-fn4-0091270010397728">
<label>a.</label>
<p>Analysis of variance.</p>
</fn>
<fn id="table-fn5-0091270010397728">
<label>*</label>
<p>RM vs PM; <italic>P</italic> = .039.</p>
</fn>
<fn id="table-fn6-0091270010397728">
<label>**</label>
<p>RM vs PM; <italic>P</italic> = .042.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section12-0091270010397728" sec-type="discussion">
<title>Discussion</title>
<p>In the present study, we first confirmed that [<sup>13</sup>C]-ABT reflected the pharmacokinetics of aminopyrine. Then we evaluated the influence of 3 PPIs on CYP activity using [<sup>13</sup>C]-ABT and found that the different PPIs influenced the activity of CYPs in different degrees and that the influence of PPIs on CYPs depended on CYP2C19 genotype status. Different PPIs were found to influence the activity of CYPs to differing degrees, and the influence of PPIs on CYP2C19 depended on genotype. We also found that a higher dose of PPI (ie, omeprazole 80 mg) seemed to induce CYPs in IMs and PMs of CYP2C19; however, <italic>P</italic> value did not reach the statistical significance because our sample size was small.</p>
<p>Various reports have described drug–drug interactions of PPIs with other drugs. McCarthy et al<sup><xref ref-type="bibr" rid="bibr8-0091270010397728">8</xref></sup> reported that concomitant use of a PPI significantly increased the incidence of adverse events for other drugs with potential for interaction with PPIs, such as warfarin, clarithromycin, and corticosteroids. Ishizaki et al<sup><xref ref-type="bibr" rid="bibr16-0091270010397728">16</xref></sup> reported that omeprazole significantly decreased the mean clearance of diazepam and increased its half-life, AUC for plasma concentration–time, and mean residence time in RMs and IMs of CYP2C19. Recently, prophylactic use of a PPI in patients treated with clopidogrel was reported to attenuate the antiplatelet function of clopidogrel, which is associated with increased risk of adverse outcomes in comparison with clopidogrel treatment without a PPI.<sup><xref ref-type="bibr" rid="bibr17-0091270010397728">17</xref></sup> Interestingly, clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole in subjects carrying CYP2C19 *1/*1 but not CYP2C19 *2/*2 or *3.<sup><xref ref-type="bibr" rid="bibr18-0091270010397728">18</xref></sup> Thus, the interaction of a PPI with other drugs thus sometimes depends on CYP2C19 genotypes, as observed in the present study.</p>
<p>The [<sup>13</sup>C]-ABT has been used to evaluate CYP activity.<sup><xref ref-type="bibr" rid="bibr19-0091270010397728">19</xref></sup> However, little study has been done on the relationship between [<sup>13</sup>C]-ABT and pharmacokinetics of [<sup>13</sup>C]-aminopyrine. The present study measured plasma [<sup>13</sup>C]-aminopyrine levels and DOB using breath samples at the same time after ingestion of [<sup>13</sup>C]-aminopyrine and confirmed that [<sup>13</sup>C]-ABT results reflect the pharmacokinetics of [<sup>13</sup>C]-aminopyrine. We are therefore sure that [<sup>13</sup>C]-ABT offers a simple, noninvasive tool to evaluate the activity of CYPs, as reported previously.<sup><xref ref-type="bibr" rid="bibr10-0091270010397728">10</xref>,<xref ref-type="bibr" rid="bibr20-0091270010397728">20</xref>,<xref ref-type="bibr" rid="bibr21-0091270010397728">21</xref></sup></p>
<p>We found that CYP2C19 is strongly involved in the metabolism of aminopyrine, as DOB differed among different CYP2C19 genotype groups: DOB in PMs of CYP2C19 was lower than RMs and IMs at baseline, indicating aminopyrine as one substrate of CYP2C19. Drug–drug interactions might thus reasonably occur between aminopyrine and other substrates of CYP2C19, such as PPIs. However, differences exist in metabolic dispositions among different PPIs, associated with the different potential for drug–drug interactions via CYPs.<sup><xref ref-type="bibr" rid="bibr22-0091270010397728">22</xref></sup> Omeprazole is mainly metabolized by CYP2C19, and lansoprazole is metabolized by CYP2C19 and CYP3A4, whereas CYPs play a smaller role in the metabolism of rabeprazole in comparison with other PPIs.<sup><xref ref-type="bibr" rid="bibr23-0091270010397728">23</xref></sup> This difference in the metabolic dispositions of 3 PPIs seemed compatible with the present results.</p>
<p>Giannini et al<sup><xref ref-type="bibr" rid="bibr10-0091270010397728">10</xref></sup> compared drug–drug interactions among omeprazole, lansoprazole, and pantoprazole (PPZ) during <italic>H pylori</italic> eradication therapy using [<sup>13</sup>C]-ABT and suggested that the administration of these PPIs and antimicrobial agents did not seem to influence global liver metabolic function, whereas omeprazole confirmed a somewhat greater inhibitory effect on [<sup>13</sup>C]-aminopyrine. Giannini et al<sup><xref ref-type="bibr" rid="bibr24-0091270010397728">24</xref></sup> also reported in another study that rabeprazole did not inhibit CYP activity in eradication of <italic>H pylori</italic> with antimicrobial agents. These investigators performed [<sup>13</sup>C]-ABT during rabeprazol in patients with gastroesophageal reflux disease and showed that 1-week, full-dose rabeprazole does not display any significant interactions with CYPs.<sup><xref ref-type="bibr" rid="bibr25-0091270010397728">25</xref></sup> The present study reconfirmed that rabeprazole has little inhibitory effect on CYP activity as assessed by [<sup>13</sup>C]-ABT. Our study also demonstrated that omeprazole and lansoprazole inhibit CYP activity. Close attention must therefore be paid to the risk of drug–drug interactions when using lansoprazole as well as omeprazole.</p>
<p>In the present study, at the usual standard doses of PPIs, omeprazole showed the most evident inhibitory effect on CYPs, particularly in IMs of CYP2C19. Interestingly, at a high dose of omeprazole (80 mg), CYP activity was most inhibited in RMs but appeared in turn slightly increased in PMs. Henry et al<sup><xref ref-type="bibr" rid="bibr26-0091270010397728">26</xref></sup> tested for drug–drug interactions at 2 dose levels of omeprazole (30 mg and 60 mg/d) using [<sup>14</sup>C]-ABT and showed that drug–drug interactions should be assessed when large doses of omeprazole are being used. In contrast, Diaz et al<sup><xref ref-type="bibr" rid="bibr27-0091270010397728">27</xref></sup> reported that omeprazole selectively increased CYP1A1 and 1A2 activities in human liver microsomes. Rost et al<sup><xref ref-type="bibr" rid="bibr28-0091270010397728">28</xref>,<xref ref-type="bibr" rid="bibr29-0091270010397728">29</xref></sup> reported that omeprazole induced CYP1A2 in a dose-independent manner. Our results suggest that omeprazole inhibits CYP activity in a dose-dependent manner in RMs but induces some CYPs, probably such as CYP1A1 and CYP1A2, in PMs. Because clearance of omeprazole is decreased in IMs and PMs in comparison with RMs, a very high concentration of omeprazole is attained in IMs and PMs when a high dose of omeprazole (ie, 80 mg) is dosed. Therefore, in IMs of CYP2C19, an increased dose of a PPI not only inhibits some CYP activity but also induces other CYPs. As a result, the inhibitory effects of PPI on CYPs appear to be offset by the induction of other CYPs. Similarly, higher plasma levels of omeprazole in PMs might further induce CYPs, and [<sup>13</sup>C]-ABT results were therefore increased by omeprazole 80 mg in PMs. When omeprazole dose was increased from 20 mg to 80 mg, the increase in plasma omeprazole level in PMs was smaller than that in RMs, indicating that other CYPs to metabolize omeprazole are induced in PMs. Therefore, we think that patterns of drug–drug interactions of PPIs are influenced by CYP2C19 genotypes as well as PPI dose.</p>
<p>Finally, the present results must be interpreted within the following study limitations. First, the duration of PPI dosing in this study was short. Second, the sample size was small. Third, subjects were young healthy volunteers, not patients. These study results must thus be considered as preliminary, and further studies are required to evaluate the clinical significance of the influence of different PPIs on CYPs. In any case, our results clearly demonstrate that short-term treatment with different PPIs inhibits CYP activity to differing degrees. Among PPIs, omeprazole and lansoprazole significantly inhibit CYPs. Moreover, the influence of PPIs on CYPs depended on CYP2C19 genotype status as well as PPI doses. Therefore, possible drug–drug interactions should be taken into consideration in relation to CYP2C19 genotype status and PPI dose when a PPI is used in patients treated with other substrates of CYP2C19. We think that [<sup>13</sup>C]-ABT could be useful for predicting drug–drug interactions. The clinical usefulness of this test should be verified in a future study.</p>
</sec>
</body>
<back>
<ack><p>We thank Ms Kageyama for her help in measuring plasma concentrations of [<sup>13</sup>C]-aminopyrine and omeprazole.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: This work was supported by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (20590718).</p>
</fn>
<fn fn-type="conflict">
<p>No authors had any conflicts of interest related to this study.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010397728">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Satoh</surname><given-names>H</given-names></name>
<name><surname>Inatomi</surname><given-names>N</given-names></name>
<name><surname>Nagaya</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1989</year>;<volume>248</volume>:<fpage>806</fpage>-<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010397728">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagaya</surname><given-names>H</given-names></name>
<name><surname>Satoh</surname><given-names>H</given-names></name>
<name><surname>Kubo</surname><given-names>K</given-names></name>
<name><surname>Maki</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Possible mechanism for the inhibition of gastric (H<sup>+</sup> + K<sup>+</sup>)-adenosine triphosphatase by the proton pump inhibitor AG-1749</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1989</year>;<volume>248</volume>:<fpage>799</fpage>-<lpage>805</lpage>.</citation>
</ref>
<ref id="bibr3-0091270010397728">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blum</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Lansoprazole and omeprazole in the treatment of acid peptic disorders</article-title>. <source>Am J Health Syst Pharm</source>. <year>1996</year>;<volume>53</volume>:<fpage>1401</fpage>-<lpage>1415</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010397728">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furuta</surname><given-names>T</given-names></name>
<name><surname>Futami</surname><given-names>H</given-names></name>
<name><surname>Arai</surname><given-names>H</given-names></name>
<name><surname>Hanai</surname><given-names>H</given-names></name>
<name><surname>Kaneko</surname><given-names>E</given-names></name>
</person-group>. <article-title>Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori</article-title>. <source>J Clin Gastroenterol</source>. <year>1995</year>;<volume>20</volume>(<issue>suppl 2</issue>):<fpage>S107</fpage>-<lpage>S111</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010397728">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>DL</given-names></name>
<name><surname>Scheiman</surname><given-names>J</given-names></name>
<name><surname>Abraham</surname><given-names>NS</given-names></name>
<etal/></person-group>. <article-title>ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>:<fpage>1894</fpage>-<lpage>1909</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010397728">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>DL</given-names></name>
<name><surname>Scheiman</surname><given-names>J</given-names></name>
<name><surname>Abraham</surname><given-names>NS</given-names></name>
<etal/></person-group>. <article-title>ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>52</volume>:<fpage>1502</fpage>-<lpage>1517</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010397728">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatt</surname><given-names>DL</given-names></name>
<name><surname>Scheiman</surname><given-names>J</given-names></name>
<name><surname>Abraham</surname><given-names>NS</given-names></name>
<etal/></person-group>. <article-title>ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use</article-title>. <source>Am J Gastroenterol</source>. <year>2008</year>;<volume>103</volume>:<fpage>2890</fpage>-<lpage>2907</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010397728">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McCarthy</surname><given-names>DM</given-names></name>
<name><surname>McLaughlin</surname><given-names>TP</given-names></name>
<name><surname>Griffis</surname><given-names>DL</given-names></name>
<name><surname>Yazdani</surname><given-names>C</given-names></name>
</person-group>. <article-title>Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450</article-title>. <source>Am J Ther</source>. <year>2003</year>;<volume>10</volume>:<fpage>330</fpage>-<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010397728">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stedman</surname><given-names>CA</given-names></name>
<name><surname>Barclay</surname><given-names>ML</given-names></name>
</person-group>. <article-title>Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2000</year>;<volume>14</volume>:<fpage>963</fpage>-<lpage>978</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010397728">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giannini</surname><given-names>E</given-names></name>
<name><surname>Romagnoli</surname><given-names>P</given-names></name>
<name><surname>Fasoli</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Influence of Helicobacter pylori eradication therapy on <sup>13</sup>C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens</article-title>. <source>Am J Gastroenterol</source>. <year>2000</year>;<volume>95</volume>:<fpage>2762</fpage>-<lpage>2767</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010397728">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Branch</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Drugs as indicators of hepatic function</article-title>. <source>Hepatology</source>. <year>1982</year>;<volume>2</volume>:<fpage>97</fpage>-<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010397728">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Irving</surname><given-names>CS</given-names></name>
<name><surname>Schoeller</surname><given-names>DA</given-names></name>
<name><surname>Nakamura</surname><given-names>KI</given-names></name>
<name><surname>Baker</surname><given-names>AL</given-names></name>
<name><surname>Klein</surname><given-names>PD</given-names></name>
</person-group>. <article-title>The aminopyrine breath test as a measure of liver function: a quantitative description of its metabolic basis in normal subjects</article-title>. <source>J Lab Clin Med</source>. <year>1982</year>;<volume>100</volume>:<fpage>356</fpage>-<lpage>373</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010397728">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mion</surname><given-names>F</given-names></name>
<name><surname>Queneau</surname><given-names>PE</given-names></name>
<name><surname>Rousseau</surname><given-names>M</given-names></name>
<name><surname>Brazier</surname><given-names>JL</given-names></name>
<name><surname>Paliard</surname><given-names>P</given-names></name>
<name><surname>Minaire</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Aminopyrine breath test: development of a <sup>13</sup>C-breath test for quantitative assessment of liver function in humans</article-title>. <source>Hepatogastroenterology</source>. <year>1995</year>;<volume>42</volume>:<fpage>931</fpage>-<lpage>938</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010397728">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kubota</surname><given-names>T</given-names></name>
<name><surname>Chiba</surname><given-names>K</given-names></name>
<name><surname>Ishizaki</surname><given-names>T</given-names></name>
</person-group>. <article-title>Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population</article-title>. <source>Clin Pharmacol Ther</source>. <year>1996</year>;<volume>60</volume>:<fpage>661</fpage>-<lpage>666</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010397728">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kodaira</surname><given-names>C</given-names></name>
<name><surname>Sugimoto</surname><given-names>M</given-names></name>
<name><surname>Nishino</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2009</year>;<volume>65</volume>:<fpage>593</fpage>-<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010397728">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishizaki</surname><given-names>T</given-names></name>
<name><surname>Chiba</surname><given-names>K</given-names></name>
<name><surname>Manabe</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation</article-title>. <source>Clin Pharmacol Ther</source>. <year>1995</year>;<volume>58</volume>:<fpage>155</fpage>-<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr17-0091270010397728">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>PM</given-names></name>
<name><surname>Maddox</surname><given-names>TM</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>301</volume>:<fpage>937</fpage>-<lpage>944</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010397728">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>BL</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Tu</surname><given-names>JH</given-names></name>
<etal/></person-group>. <article-title>Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms</article-title>. <source>J Clin Pharmacol</source>. <year>2009</year>;<volume>49</volume>:<fpage>574</fpage>-<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr19-0091270010397728">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schneider</surname><given-names>JF</given-names></name>
<name><surname>Schoeller</surname><given-names>DA</given-names></name>
<name><surname>Nemchausky</surname><given-names>B</given-names></name>
<name><surname>Boyer</surname><given-names>JL</given-names></name>
<name><surname>Klein</surname><given-names>P</given-names></name>
</person-group>. <article-title>Validation of <sup>13</sup>CO<sub>2</sub> breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man</article-title>. <source>Clin Chim Acta</source>. <year>1978</year>;<volume>84</volume>:<fpage>153</fpage>-<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr20-0091270010397728">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fasoli</surname><given-names>A</given-names></name>
<name><surname>Giannini</surname><given-names>E</given-names></name>
<name><surname>Botta</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title><sup>13</sup>CO<sub>2</sub> excretion in breath of normal subjects and cirrhotic patients after <sup>13</sup>C-aminopyrine oral load: comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis</article-title>. <source>Hepatogastroenterology</source>. <year>2000</year>;<volume>47</volume>:<fpage>234</fpage>-<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr21-0091270010397728">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giannini</surname><given-names>E</given-names></name>
<name><surname>Fasoli</surname><given-names>A</given-names></name>
<name><surname>Chiarbonello</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title><sup>13</sup>C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2002</year>;<volume>16</volume>:<fpage>717</fpage>-<lpage>725</lpage>.</citation>
</ref>
<ref id="bibr22-0091270010397728">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McColl</surname><given-names>KE</given-names></name>
<name><surname>Kennerley</surname><given-names>P</given-names></name>
</person-group>. <article-title>Proton pump inhibitors—differences emerge in hepatic metabolism</article-title>. <source>Dig Liver Dis</source>. <year>2002</year>;<volume>34</volume>:<fpage>461</fpage>-<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr23-0091270010397728">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishizaki</surname><given-names>T</given-names></name>
<name><surname>Horai</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole</article-title>. <source>Aliment Pharmacol Ther</source>. <year>1999</year>;<volume>13</volume>(<issue>suppl 3</issue>):<fpage>27</fpage>-<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr24-0091270010397728">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giannini</surname><given-names>EG</given-names></name>
<name><surname>Malfatti</surname><given-names>F</given-names></name>
<name><surname>Botta</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on <sup>13</sup>C-aminopyrine breath test</article-title>. <source>Dig Dis Sci</source>. <year>2005</year>;<volume>50</volume>:<fpage>1207</fpage>-<lpage>1213</lpage>.</citation>
</ref>
<ref id="bibr25-0091270010397728">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giannini</surname><given-names>EG</given-names></name>
<name><surname>Savarino</surname><given-names>V</given-names></name>
<name><surname>Testa</surname><given-names>R</given-names></name>
</person-group>. <article-title>Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastroesophageal reflux disease</article-title>. <source>Dig Dis Sci</source>. <year>2006</year>;<volume>51</volume>:<fpage>1602</fpage>-<lpage>1606</lpage>.</citation>
</ref>
<ref id="bibr26-0091270010397728">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>DA</given-names></name>
<name><surname>Somerville</surname><given-names>KW</given-names></name>
<name><surname>Kitchingman</surname><given-names>G</given-names></name>
<name><surname>Langman</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Omeprazole: effects on oxidative drug metabolism</article-title>. <source>Br J Clin Pharmacol</source>. <year>1984</year>;<volume>18</volume>:<fpage>195</fpage>-<lpage>200</lpage>.</citation>
</ref>
<ref id="bibr27-0091270010397728">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Diaz</surname><given-names>D</given-names></name>
<name><surname>Fabre</surname><given-names>I</given-names></name>
<name><surname>Daujat</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450</article-title>. <source>Gastroenterology</source>. <year>1990</year>;<volume>99</volume>:<fpage>737</fpage>-<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr28-0091270010397728">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rost</surname><given-names>KL</given-names></name>
<name><surname>Brosicke</surname><given-names>H</given-names></name>
<name><surname>Brockmoller</surname><given-names>J</given-names></name>
<name><surname>Scheffler</surname><given-names>M</given-names></name>
<name><surname>Helge</surname><given-names>H</given-names></name>
<name><surname>Roots</surname><given-names>I</given-names></name>
</person-group>. <article-title>Increase of cytochrome P450IA2 activity by omeprazole: evidence by the <sup>13</sup>C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin</article-title>. <source>Clin Pharmacol Ther</source>. <year>1992</year>;<volume>52</volume>:<fpage>170</fpage>-<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr29-0091270010397728">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rost</surname><given-names>KL</given-names></name>
<name><surname>Brosicke</surname><given-names>H</given-names></name>
<name><surname>Heinemeyer</surname><given-names>G</given-names></name>
<name><surname>Roots</surname><given-names>I</given-names></name>
</person-group>. <article-title>Specific and dose-dependent enzyme induction by omeprazole in human beings</article-title>. <source>Hepatology</source>. <year>1994</year>;<volume>20</volume>:<fpage>1204</fpage>-<lpage>1212</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>